Patient | Months Receiving TCZ-IV | Months Receiving TCZ-SC | Medications while Receiving TCZ (IV and SC) | Months Until Flare* while Receiving TCZ-SC Treatment | Type of Relapse | JADAS-10 Course after TCZ-SC | Course of Uveitis Activity* | ||
---|---|---|---|---|---|---|---|---|---|
Baseline | Last Followup | Baseline | Last Followup | ||||||
1 | 29 | 5 | Cyclosporine, corticosteroid eyedrops | 1 | Joint | 0 | 3.5 | AC cell grade 0/0 Flare 0/0 VA 0/0.3 | AC cell grade 0/0 Flare 0/0 VA 0/0.3 |
2 | 38 | 7 | Leflunomide | 7 | Ocular | 6.5 | 10.5 | AC cell grade 0/0 Flare 0/0 VA 1/1 | AC cell grade 2+/0 Flare 0/0 VA 1/1 |
3 | 63 | 5 | Corticosteroid eyedrops | 3/5† | Joint/ocular | 0 | 10 | AC cell grade NA/NA Flare NA/NA VA 0/0.2 | AC cell grade NA/NA Flare NA/NA VA 0/0 |
4 | 25 | 6 | Leflunomide | 6 | Ocular | 0 | 5 | AC cell grade 0/0 Flare 0/0 VA 0.9/0.5 | AC cell grade 0/2+ Flare 0/1+ VA 0.9/0.3 |
↵* Uveitis activity determined according to Standardization Uveitis Working Group (SUN) criteria10. Ocular flare was defined according to the definition provided by SUN as “two-step increase in level of inflammation or increase from grade 3+ to 4+.” Joint flare was based on the already published preliminary definition of flare as “worsening in any 2/6 core response variables (CRV) by ≥ 40% without concomitant improvement of more than one of the remaining CRV by ≥ 30%”11. The 6 CRV are no. joints with active arthritis, no. joints with limited range of motion, physician global assessment of disease severity, parent or patient global assessment, 1 laboratory marker of inflammation, and the score of a functional assessment tool.
↵† 3 months until joint flare, 5 months until ocular flare (vitreous hemorrhage). JIA: juvenile idiopathic arthritis; AC: anterior chamber; JADAS: Juvenile Arthritis Disease Activity Score; NA: nonassessable; TCZ-IV: intravenous tocilizumab; TCZ-SC: subcutaneous TCZ; VA: visual acuity.